Redefine X-linked hypophosphatemia (XLH) treatment with a targeted therapy

CRYSVITA® (burosumab-twza) is a therapy for XLH that addresses the underlying cause of the disease.

CRYSVITA is the first and only FDA-approved therapy indicated for the treatment of XLH in adult and pediatric patients 1 year of age and older.1

CRYSVITA efficacy and safety have been studied in children and adults with XLH.

Discover CRYSVITA for your patients.

Redefine X-linked hypophosphatemia (XLH) treatment with a targeted therapy

CRYSVITA® (burosumab-twza) is a therapy for XLH that addresses the underlying cause of the disease.

CRYSVITA is the first and only FDA-approved therapy indicated for the treatment of XLH in adult and pediatric patients 1 year of age and older.1

CRYSVITA efficacy and safety have been studied in children and adults with XLH.

Discover CRYSVITA for your patients.

CRYSVITA® (burosumab-twza) antibody

CRYSVITA® (burosumab-twza) is a breakthrough XLH therapy that addresses the underlying cause of the disease

How CRYSVITA may work

Learn about how the proposed mechanism of action (MOA) of CRYSVITA on excess fibroblast growth factor 23 (FGF23)

View the Proposed MOA
UltraCare Guides help patients navigate access to their treatment
UltraCare Guides help patients navigate access to their treatment

Help your patients gain access to CRYSVITA

UltraCare™ Patient Services for CRYSVITA is a program that provides information about how you and your patients can have access to CRYSVITA. Our services are designed to help patients and caregivers understand their insurance coverage and determine their eligibility for financial and patient assistance programs.

Visit UltraCare
Reference
  1. CRYSVITA (burosumab-twza) US Prescribing Information; April 2018.